09.08.26 -- Choose New Analytical Technologies At The Right Stage Of Development

Explore connector solutions for sterility, chemical compatibility, and ultra-low temperature challenges when setting up a therapeutic process for long-term success.

Learn about the development of a serum-free suspension MDCK cell line that serves as an optimal platform for isolating human influenza viruses from clinical samples and producing vaccines at scale.

Traditional viral vector production presents scalability risks. Address yield limitations using an upstream AAV processing platform tailored for gene therapy manufacturing.

Examine quantitative single-vesicle profiling methods that reveal tissue-specific surface marker expression patterns invisible to bulk EV analysis, with molecular-level resolution across three MSC sources.

Uncover how particle levels remained stable during 24 hours of high-speed mixing, even under extreme temperatures, confirming a system’s suitability for final fill and other particulate-sensitive applications.

Demand for EVs is rising due to their therapeutic promise. Compare two scalable platforms that address production challenges to support EVs' expanding clinical and commercial applications.

Production bottlenecks stall life-saving treatments. See how real-time monitoring and quality data power AI strategies to accelerate cell and gene therapy manufacturing.

Expand access to cost-effective lentiviral vectors. This space-efficient processing method offers multi-fold yield gains to streamline commercial therapy production.

Evaluate challenges and solutions in developing novel AAV capsids, focusing on manufacturing complexity, analytical testing, and regulatory considerations for advancing gene therapy effectiveness.

Run-to-run AAV titer variability can jeopardize production. Controlling incubation timing, DNA input, and media conditions improves yield and batch consistency.

Inconsistent expression stalls clinical progress. Learn how streamlined vector backbones improve editing durability and process consistency when reliability matters most.

Have you thought about how the materials chosen for the tubing, transfer sets, single-use bags, and manifolds in therapy manufacturing could enhance your processes?

An essential part of AAV vector production is the characterization of potential CQAs. Discover novel, robust, and orthogonal methods that can be used to assess identity, purity, and residuals.